Researchers say they have used a precise genome-editing technique called base editing to alter the genome of human embryos for the first time, an announcement that prompted both excitement and dismay.
https://t.co/9G4WMAsKUQ
Loving the open-access release of @MITPress's new volume on Dennett’s Real Patterns: https://t.co/SxUTvxCIUl
It's the perfect primer for our forthcoming volume, "Embodied Intelligence" (out June 23rd!). 🧠
Once you explore how data structures and patterns define nature, join us to see how biological and artificial agents use those very architectures to navigate, sense, and act in the world. 🤖6/23/26
https://t.co/ZyYxflsWrj
#OpenAccess #MITPress. #EmbodiedIntelligence #CognitiveScience #ActiveInference
Doctors are billing daraxonrasib as a “revolution” in cancer treatment, following trial results that were said to have left scientists in tears.
Terminally ill patients who took the drug were three times more likely to still be alive after a year than those who received standard chemotherapy ⤵️
https://t.co/CTEeTBt4y8
🚀 Immunotherapy is evolving rapidly beyond traditional ICIs, with exciting advances in bispecifics, cellular therapies, cancer vaccines, oncolytic viruses, and other novel approaches at #ASCO26
It has been a great learning experience by covering these developments on behalf of @sitcancer and help bring key updates in Immunotherapy from across cancer types to the SITC community.
#Immunotherapy #ASCO26 #Oncology
@SylvesterCancer@GlopesMd@Latinamd@HemOncMiami@AksheeBatra@OncBrothers@OncoDailyIO
Our Day-1 blog:
https://t.co/dsapKmNdcd
Just published @NatureMedicine and presented @ASCO
Advanced, refractory solid cancers treated with a bispecific T cell engager (BiTE, Figure), Phase 1 trial, with or without Keytruda, in 61 patients. Some very favorable responses with "manageable safety profile"
https://t.co/MkzQXY1psA
#ASCO26 Two practice-changing thoracic presentations on my radar today👀🧬📢
• LIBRETTO-432: Can adjuvant selpercatinib become the next targeted therapy standard in resected RET+ NSCLC?
• HARMONi-6: Will ivonescimab finally translate its impressive activity into an overall survival advantage in advanced squamous NSCLC?
Looking forward to the data⁉️
@OncoAlert@StephenVLiu@OncoReporte@MedwatchKate@weoncologists@Larvol@OncUpdates
NEW: Oxford researchers have helped to achieve a world first: loading a complete genome onto a quantum computer. This makes an important step towards a future where quantum computing accelerates biological discovery.
Find out more ⬇️
https://t.co/5DROjxivgr
Delighted to share that Lung Cancer Europe’s abstract has been accepted for presentation at #WCLC26 in Seoul.
“Lung Cancer and Mental Health: A European Perspective” draws on survey findings from more than 2,200 people affected by #lungcancer across 31 European countries.
Mental health support must be part of lung cancer care. #LCSM
Challenging medical dogma, our understanding of the thymus and its impact on our health throughout lifespan has been completely revamped
w/ @HugoAerts@TheLancet
https://t.co/Wx4n7zeJwp
More than 140,000 fake citations across four research repositories were identified in papers and preprints published in 2025 alone
https://t.co/nEdDM4JBVD
🧬 "Humans did not evolve to exercise — that is, to undertake discretionary physical activity for the sake of health and fitness."
🏃 Instead, humans evolved in energy-limited conditions to be physically active primarily when it was necessary and to otherwise avoid nonessential and unrewarding physical activity.
🤔"The disinclination to exercise is often a normal instinct but has become a mismatch in the modern environments"
An interesting perspective in JAMA:
https://t.co/F3LaP9B7qo
Spending more time outside? Here’s what to know about ticks.
As tick populations grow, Yale epidemiologist Peter Krause breaks down which diseases are spreading, which are rare but dangerous, and how to protect yourself and your family.
Learn what to know before heading outdoors: https://t.co/m4svdISKkN